Insights
Resources & News
Is your healthcare product market-ready?
New healthcare products often face challenges in gaining market acceptance, especially if they combine multiple types, like drugs, devices, diagnostics or digital tools. The most innovative products may face the biggest hurdles because there are no existing examples...
Driving launch excellence with agile transformation
Launching a biopharmaceutical product globally always involves significant uncertainty - especially before pivotal clinical trial results confirm efficacy. Risks arise at every stage: R&D setbacks, unclear healthcare demand, unpredictable competitors and...
Tackling the antibiotic resistance crisis
Bacteria are rapidly developing resistance to the antibiotics they are exposed to. Alexander Fleming discovered penicillin in 1928, and during his Nobel lecture on 11 December 1945, he had already warned about the potential dangers of antibiotic resistance, saying:...
Product launches: making the most of your one shot
The importance of a pharma product’s launch to its success cannot be overstated. A recent analysis by Deloitte showed that most new drugs continue with the revenue trajectory set at launch – around 70% of products that miss expectations at launch continue doing so in...
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Digital healthcare is a booming industry. According to one recent report, the global digital healthcare market is projected to grow from an estimated $147bn in 2019 to $234.5bn in 2023. If we look at apps alone (which is just one element of digital healthcare), there...
On our best behaviour: Why driving behaviour change is the next big focus for pharma companies in chronic diseases
"Drugs don't work in patients that don'0t take them" Everett Koop, former US Surgeon General. This famous quote from 1985 has perhaps never been more relevant. It is estimated that non-adherence to medication is associated with almost 200,000 deaths in Europe each...
Towards a smoker segmentation tool: Analysis of predictors for risk of harm, readiness to quit and optimal methods to quit smoking
Although most people who smoke cigarettes want to quit, stopping smoking is notoriously difficult. There are a huge number of individual factors – including smoking history and behaviors, biological, psychological, socioeconomic and demographic factors – that drive...
Assessing the impact of smoking cessation interventions on smoking prevalence – Lessons from five successful and five less successful countries
Smoking remains the single largest cause of preventable death and the biggest cause of cancer worldwide (WHO Report on the Global Tobacco Epidemic. 2008). It is also the cause of many preventable illnesses, including cardiovascular disease, stroke and chronic...
Rare diseases: the seamless go-to-market model
Collectively, rare diseases are anything but rare. Combined, they represent a huge market; one that has been a major focus of interest and investment from the biopharmaceutical industry ever since the US Orphan Drug Act offered financial, legal and legislative...
Insights
Weekly Free Business Resources
If you want to receive weekly business resources and news, please subscribe to our Insights blog.
Almasan AG
The right support for the pharma/ biotech, medtech/ diagnostics, life sciences and healthcare sectors at the right time in the right way: Advisory, Interim Management and Contracting/ Outsourcing.